Intensive care unit management: Renal replacement therapy, ventilator management, volume assessment, and optimal management of hypotension
Mitra K. Nadim, Jody C. Olson – 30 March 2017
Causality Assessment for Suspected Drug‐Induced Liver Injury in Patients With Underlying Chronic Liver Disease
Lara Dakhoul, Naga Chalasani – 30 March 2017
A functional mammalian target of rapamycin complex 1 signaling is indispensable for c‐Myc‐driven hepatocarcinogenesis
Pin Liu, Mengmeng Ge, Junjie Hu, Xiaolei Li, Li Che, Kun Sun, Lili Cheng, Yuedong Huang, Maria G. Pilo, Antonio Cigliano, Giovanni M. Pes, Rosa M. Pascale, Stefania Brozzetti, Gianpaolo Vidili, Alberto Porcu, Antonio Cossu, Giuseppe Palmieri, Maria C. Sini, Silvia Ribback, Frank Dombrowski, Junyan Tao, Diego F. Calvisi, Ligong Chen, Xin Chen – 30 March 2017 – Amplification and/or activation of the c‐Myc proto‐oncogene is one of the leading genetic events along hepatocarcinogenesis.
Does the dose and type of nonselective beta‐blocker really matter?
Pramod Kumar, Sunil Taneja, Virendra Singh – 30 March 2017
Unexpected viral relapses in hepatitis C virus–infected patients diagnosed with hepatocellular carcinoma during treatment with direct‐acting antivirals
Alessandro Soria, Massimiliano Fabbiani, Giuseppe Lapadula, Andrea Gori – 30 March 2017
Monotherapy with tenofovir disoproxil fumarate for multiple drug‐resistant chronic hepatitis B: 3‐year trial
Young‐Suk Lim, Yung Sang Lee, Geum‐Youn Gwak, Kwan Soo Byun, Yoon Jun Kim, Jonggi Choi, Jihyun An, Han Chu Lee, Byung Chul Yoo, So Young Kwon – 30 March 2017 – Combination therapy has been recommended for the treatment of patients harboring multiple drug‐resistant hepatitis B virus (HBV). However, we recently demonstrated that monotherapy with tenofovir disoproxil fumarate (TDF) for 48 weeks displayed noninferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with HBV resistant to multiple drugs, including ETV and adefovir.
Polyphenic trait promotes liver cancer in a model of epigenetic instability in mice
Marco Cassano, Sandra Offner, Evarist Planet, Alessandra Piersigilli, Suk Min Jang, Hugues Henry, Markus B. Geuking, Catherine Mooser, Kathy D. McCoy, Andrew J. Macpherson, Didier Trono – 30 March 2017 – Hepatocellular carcinoma (HCC) represents the fifth‐most common form of cancer worldwide and carries a high mortality rate attributed to lack of effective treatment. Males are 8 times more likely to develop HCC than females, an effect largely driven by sex hormones, albeit through still poorly understood mechanisms.
Hypoxia mediates mitochondrial biogenesis in hepatocellular carcinoma to promote tumor growth through HMGB1 and TLR9 interaction
Samer Tohme, Hamza O. Yazdani, Yao Liu, Patricia Loughran, Dirk J. van der Windt, Hai Huang, Richard L. Simmons, Sruti Shiva, Sheng Tai, Allan Tsung – 30 March 2017 – The ability of cancer cells to survive and grow under hypoxic conditions has been known for decades, but the mechanisms remain poorly understood. Under certain conditions, cancer cells undergo changes in their bioenergetic profile to favor mitochondrial respiration by activating the peroxisome proliferator–activated receptor gamma coactivator 1 alpha (PGC‐1α) and up‐regulating mitochondrial biogenesis.
Developing a relationship with a liver transplant program
Mitchell L. Shiffman, Nadege T. Gunn – 30 March 2017
Interferon‐alpha‐induced hepatitis C virus clearance restores p53 tumor suppressor more than direct‐acting antivirals
Yucel Aydin, Animesh Chatterjee, Partha K Chandra, Srinivas Chava, Weina Chen, Anamika Tandon, Asha Dash, Milad Chedid, Martin W Moehlen, Frederic Regenstein, Luis A Balart, Ari Cohen, Hua Lu, Tong Wu, Srikanta Dash – 28 March 2017 – The mechanism why hepatitis C virus (HCV) clearance by direct‐acting antivirals (DAAs) does not eliminate the risk of hepatocellular carcinoma (HCC) among patients with advanced cirrhosis is unclear. Many viral and bacterial infections degrade p53 in favor of cell survival to adapt an endoplasmic reticulum (ER)‐stress response.